Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OneMedNet's ROE % for the quarter that ended in Mar. 2026 was 0.00%. OneMedNet's PB Ratio for the quarter that ended in Mar. 2026 was N/A.
OneMedNet's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.
OneMedNet ROE % Adjusted to Book Value Related Terms
OneMedNet ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for OneMedNet's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONMD vs CRVW, BEAT, VASO: ROE % Adjusted to Book Value Comparison
For the Health Information Services subindustry, OneMedNet's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OneMedNet ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, OneMedNet's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where OneMedNet's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
OneMedNet (ONMD) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OneMedNet and its competitors.
Is OneMedNet's ROE % Adjusted to Book Value too high?
OneMedNet's current ROE % Adjusted to Book Value is 0.00%. Overall, OneMedNet has a GF Score™ of 8/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OneMedNet's ROE % Adjusted to Book Value compare to CRVW and BEAT?
OneMedNet's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on OneMedNet and its competitors. OneMedNet's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneMedNet stock overvalued right now?
Based on GuruFocus' analysis, OneMedNet (ONMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.57, compared to a current price of $0.65 — trading 13.9% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. OneMedNet's overall GF Score™ is 8/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For OneMedNet (ONMD), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OneMedNet (ONMD) Overvalued in 2026?
Based on GuruFocus' analysis, OneMedNet stock appears to be overvalued.
The current stock price of $0.65 is trading 13.9% above its estimated GF Value™ of $0.57.
GuruFocus considers OneMedNet to be Modestly Overvalued.
Key valuation signals for ONMD:
ROE % Adjusted to Book Value: 0.00%
GF Value™: $0.57 vs. price of $0.65 (13.9% above fair value)
No single metric tells the full story. See the ONMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. Its technology has provens the commercial and regulatory viability of imaging Real World Data, an emerging market, and provides regulatory-grade, image-centric iRWDTM. Geographically, it operates in Americas, Europe and Middle East, and Asia Pacific. It derives maximum revenue from Europe and Middle East.
8GF Score
Get the complete analysis for ONMD
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONMD has been successfully added to your 
